A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice

International Journal of Clinical Practice

Volumn 53, Issue 6, 1999, Pages 413-416

  Jones, Roger ^a   Tait, C ^a   Sladen, G ^a   Weston Baker, J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; COMPUTER MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPEPSIA; ENDOSCOPY; FOLLOW UP; GENERAL PRACTICE; HEALTH CARE COST; HELICOBACTER PYLORI; HUMAN; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; COMPUTER SIMULATION; COSTS AND COST ANALYSIS; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; FAMILY PRACTICE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; REFERRAL AND CONSULTATION;

EID: 0032829582     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Buckley M, O'Morain C. Helicobacter pylori eradication: a surrogate marker for duodenal ulcer healing. Eur J Gastroenterol Hepatol 1996; 8: 415-416.
2. Van der Hulst RW, Tytgat GM. Helicobacter pylori and peptic ulcer disease. Scand J Gastroenterol 1996; 220(suppl): 10-18.
3. Penston JG. Clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol Therapeut 1996; 10: 469-486.
4. Labenz J, Tillenburg B, Peitz U, Borsch G. Long term consequences of Helicobacter pylori eradication: clinical aspects. Scand J Gastroenterol 1996; 215(suppl): 111-115.
5. Sahay P, Axon AT. Non-ulcer dyspepsia: does Helicobacter pylori matter? Postgrad Med J 1995; 71: 262-264.
6. Laheij RJ, Jansen JB, van de Lisdonk EH et al. Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1996; 10: 843-850.
7. Fendrick AM, Chernew ME, Hirth RA, Bloom BS. Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost effectiveness using decision analysis. Yale J Biol Med 1996; 69: 187-195.
8. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996; 110: 72-83.
9. Sonnenberg A, Townsend WF, Muller AD. Evaluation of dyspepsia and functional gastrointestinal disorders: a cost-benefit analysis of different approaches. Eur J Gastroenterol Hepatol 1995; 7: 655-659.
10. Tait CL, Jones RH. Decision analytic modelling of dyspepsia management strategies. Gastoenterology 1997; 112: A45.
11. Ofman JJ, Etchason J, Fullerton S et al. Management strategies for Helicobacter pylori-seropositive patient with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126: 280-291.
12. Ebell MH, Warbasse L, Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Fam Pract 1997; 44: 545-555.
13. Reilly TG, Poxon V, Sanders DS et al. Comparison of serum, salivary and rapid whole blood diagnostic tests for Helicobacter pylori and their validation against endoscopy-based tests. Gut 1997; 40: 454-458.
14. Moayyedi P, Carter AM, Catto A et al. Validation of a rapid whole blood test for diagnosing Helicobacter pylori infection. BMJ 1997; 314: 119.
15. Jones R, Phillips I, Felix G, Tait C. An evaluation of near-patient testing for Helicobacter pylori in general practice. Aliment Pharmacol Therap 1997; 11: 101-105.
16. Axon AT, Bell GD, Jones RH et al. Guidelines on appropriate indications for upper gastrointestinal endoscopy. BMJ 1995; 310: 816-817